TG Therapeutics (TGTX) Q2 2025: BrionV Share Hits 33%, Sub-Q Launch Targets $8B MS Market Expansion

August 4, 2025 | By EarningsIQ Research

BrionV adoption accelerated in Q2 as TG Therapeutics deepened its penetration in the $8 billion U.S. anti-CD20 MS market, now capturing one in three new IV starts. Strategic investments in subcutaneous (sub-Q) formulation and direct-to-consumer outreach signal a drive to expand share and address shifting payer and patient preferences. Management’s guidance raise and pipeline progress underscore a multi-year growth runway, but execution on sub-Q and payer trends will dictate the pace and durability of future gains.

Summary

• BrionV Market Penetration Surges: Now prescribed to nearly one-third of new IV anti-CD20 MS patients, reflecting strong commercial execution.
• Sub-Q BrionV Program Gains Momentum: Clinical and device milestones set up TG for entry into the self-administered segment, broadening addressable market.
• Guidance Raised Amid Pipeline Investment: Full-year outlook lifted as commercial and R&D spend intensifies to lock in future growth levers.

Performance Analysis

TG Therapeutics delivered a standout quarter, with total revenue hitting $141.1 million, driven by 91% year-over-year growth in BrionV, its intravenous (IV) anti-CD20 therapy for relapsing multiple sclerosis (MS). BrionV’s U.S. net sales reached $138.8 million, and sequential quarterly growth of 16% was fueled primarily by volume, not price, as hospital segment expansion outpaced other channels. The company’s gross-to-net ratio remained at the lower end of guidance due to higher exposure to government-mandated discounting, especially in the 340B hospital segment.

Operating expenses rose to support both commercial scaling and pipeline advancement, notably the sub-Q BrionV program and a national television campaign. Despite the increased investment, net income expanded to $28.2 million, reflecting both top-line strength and disciplined cost management. Cash reserves held steady at $279 million, preserving flexibility for continued pipeline investment and commercial expansion.

• U.S. BrionV Sales Growth Outpaces Market: Expansion in both prescriber base and new patient enrollments, with highest-ever hub enrollments since launch.
• Hospital Channel Drives Mix Shift: Fastest-growing segment, but brings higher mandated discounts, impacting gross-to-net realization.
• Persistence and Repeat Prescribing Remain Robust: Above expectations at week 24 and preliminary week 48, supporting durable revenue base.

Management’s raised revenue guidance and continued investment in both commercial and R&D initiatives highlight a business model focused on scaling share while preparing for market shifts toward self-administered therapies.

Executive Commentary

Strategic Positioning

1. BrionV as Core Growth Engine

BrionV, TG’s IV anti-CD20 therapy, has rapidly gained share in the relapsing MS market, now accounting for about 33% of new IV anti-CD20 patient starts. The product’s twice-yearly, one-hour infusion schedule and five-year safety data resonate with both patients and providers, supporting adoption across academic centers, private practices, and the VA system. Commercial team discipline and a multi-channel marketing approach, including a national TV campaign, are amplifying brand awareness and patient-driven demand.

2. Sub-Q BrionV: Expanding Addressable Market

The subcutaneous (sub-Q) BrionV program is TG’s next major lever. With up to 40% of the anti-CD20 market preferring a self-administered option, TG is targeting this segment with a pivotal phase three trial for sub-Q BrionV, including both every-other-month and quarterly dosing schedules. The company expects to complete enrollment in 2026, file for approval in 2027, and potentially launch in 2028, positioning itself as the only company offering both IV and self-administered anti-CD20 options in MS.

3. Enhancing Patient Experience and Pipeline Diversification

Pipeline initiatives focus on both convenience and new indications. The “Enhanced” study aims to simplify IV BrionV dosing, consolidating two initial infusions into one, which could improve patient and provider experience and drive further adoption. Meanwhile, the company is advancing Azercel, an allogeneic CD19-directed CAR-T therapy, into early clinical trials for progressive MS, and exploring BrionV in myasthenia gravis, signaling intent to broaden its neurology portfolio.

4. Commercial Execution and Brand Building

Direct-to-consumer investments, such as the national TV campaign, are yielding measurable increases in patient awareness and branded search activity. Field team effectiveness, validated by high peer ratings, is translating into deeper account penetration and sustained prescriber engagement, supporting a durable commercial franchise.

Key Considerations

This quarter underscores TG’s dual focus on driving near-term BrionV adoption and preparing for a pivotal market shift toward self-administered therapies. The company’s ability to maintain momentum in IV while investing in sub-Q and pipeline assets will define its competitive position through 2028 and beyond.

Key Considerations:

• Market Share Acceleration: BrionV’s capture of one-third of new IV anti-CD20 starts reflects strong execution but also signals a maturing channel, with future growth increasingly dependent on accessing the self-administered segment.
• Gross-to-Net Headwinds: Expansion in the hospital segment, while driving volume, is exposing TG to higher government-mandated discounts, potentially capping margin expansion.
• Sub-Q Execution Risk: Timely completion of pivotal trials and successful device integration (auto-injector) are critical to unlocking the next growth phase and defending share as payer and patient preferences evolve.
• Pipeline Optionality: Early-stage efforts in CAR-T and new indications offer long-term upside but require sustained investment and carry clinical development risk.

Risks

Key risks include execution delays or regulatory setbacks in the sub-Q BrionV program, which could limit TG’s ability to capture the growing self-administered segment. Increasing exposure to government discounting in the hospital channel may compress margins, while competitive dynamics—especially payer-driven shifts favoring at-home therapies—could accelerate market transition before TG’s sub-Q launch. Pipeline bets in CAR-T and new indications remain high-risk, long-timeline endeavors.

Forward Outlook

For Q3, TG Therapeutics did not provide specific guidance but indicated:

• Seasonal moderation in Q3, with stronger sequential growth expected from Q3 to Q4.
• Continued expansion in new patient enrollments and high persistence rates supporting revenue durability.

For full-year 2025, management raised BrionV U.S. net revenue guidance to $570 to $575 million, citing:

• Sustained momentum in both new and repeat prescriptions.
• Impact from multi-channel marketing and expanding prescriber base.

Management highlighted several factors that will shape second-half performance, including the seasonality of MS prescribing, further penetration in the hospital segment, and ongoing investments in brand awareness and pipeline development.

Takeaways

TG’s commercial engine is firing on all cylinders, but the next leg of growth hinges on flawless execution in sub-Q development and adaptation to evolving payer and patient dynamics.

• BrionV’s Penetration Sets Strong Foundation: The brand’s rapid uptake and high persistence rates have established a robust revenue base, but future share gains in the IV segment may slow as the market matures.
• Sub-Q Launch Will Define Next Growth Phase: Success in the pivotal sub-Q trial and device integration is critical to tapping the 35-40% of the market demanding self-administration and defending against payer-driven shifts.
• Watch for Payer and Channel Evolution: Investors should monitor signs of accelerated payer preference for at-home therapies, as well as gross-to-net trends as hospital segment exposure rises.

Conclusion

TG Therapeutics delivered a quarter marked by commercial outperformance and strategic investment in future growth levers. The company’s raised guidance and pipeline progress reinforce its leadership ambitions in MS, but the transition to the sub-Q era and evolving payer landscape will test its ability to sustain momentum and defend share.

Industry Read-Through

TG’s experience highlights several key trends for the neurology and specialty pharma sectors. The shift toward self-administered therapies is accelerating, driven by both patient preference and payer incentives. Companies reliant on physician-administered infusions must rapidly innovate or risk ceding ground to more convenient alternatives. Direct-to-consumer marketing is becoming essential for specialty brands aiming to drive patient-driven demand. Finally, expanding exposure to government-mandated discounts in the hospital channel is a growing headwind across the sector, requiring careful management of channel mix and pricing strategies. Competitors and investors should closely watch how TG navigates the sub-Q launch and payer dynamics, as these forces are likely to reshape the broader MS and autoimmune therapy landscape.

TGTX Healthcare Biotechnology Neurology Multiple sclerosis Pipeline Self-administration Brand building